GlycoMimetics Inc
NASDAQ:GLYC

Watchlist Manager
GlycoMimetics Inc Logo
GlycoMimetics Inc
NASDAQ:GLYC
Watchlist
Price: 0.157 USD -99.05% Market Closed
Market Cap: 10.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of GLYC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLYC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
3
Median 3Y
377.3
Median 5Y
64.3
Industry
7.9
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-1.4
Industry
23.7
Forward
-0.3
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-1.6
Industry
22
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-1.6
Industry
23.8
vs History
34
vs Industry
29
Median 3Y
2
Median 5Y
1.5
Industry
3.3
vs History
vs Industry
1
Median 3Y
-1 381.5
Median 5Y
-109.9
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
34
vs Industry
18
Median 3Y
-0.2
Median 5Y
-0.1
Industry
6.4
vs History
34
vs Industry
16
Median 3Y
-0.2
Median 5Y
-0.1
Industry
7
Forward
0
vs History
34
vs Industry
21
Median 3Y
-0.2
Median 5Y
-0.1
Industry
8.3
vs History
34
vs Industry
17
Median 3Y
-0.2
Median 5Y
-0.1
Industry
6.5
vs History
vs Industry
2
Median 3Y
13.4
Median 5Y
1.3
Industry
5.7

Multiples Across Competitors

GLYC Competitors Multiples
GlycoMimetics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
GlycoMimetics Inc
NASDAQ:GLYC
10.1m USD 0 -0.3 0 0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 786 100.8 -160 580.3 -194 995.7 -192 770.6
US
Abbvie Inc
NYSE:ABBV
396.4B USD 6.6 168.8 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
175.4B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.2B USD 9.7 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 085.2 -532.1 -579.4 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
45.6B EUR 14.8 34.9 60.3 62
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.7B USD 16.1 1 186.2 155.7 188.9
P/S Multiple
Revenue Growth P/S to Growth
US
GlycoMimetics Inc
NASDAQ:GLYC
Average P/S: 3 378 825.2
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 786 100.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 085.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.8
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
P/E Multiple
Earnings Growth PEG
US
GlycoMimetics Inc
NASDAQ:GLYC
Average P/E: 187.5
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 580.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.9
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 186.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
GlycoMimetics Inc
NASDAQ:GLYC
Average EV/EBITDA: 35
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 995.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
60.3
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.7
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
GlycoMimetics Inc
NASDAQ:GLYC
Average EV/EBIT: 40.3
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 770.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
62
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.9
N/A N/A